John Doyle - Cognition Therapeutics Chief Officer
| CGTX Stock | USD 0.43 0.01 2.27% |
Executive
John Doyle is Chief Officer of Cognition Therapeutics
| Age | 47 |
| Address | 2500 Westchester Ave., Purchase, NY, United States, 10577 |
| Phone | 412 481 2210 |
| Web | https://www.cogrx.com |
John Doyle Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Doyle against Cognition Therapeutics stock is an integral part of due diligence when investing in Cognition Therapeutics. John Doyle insider activity provides valuable insight into whether Cognition Therapeutics is net buyers or sellers over its current business cycle. Note, Cognition Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cognition Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Doyle over six months ago Disposition of 8699 shares by John Doyle of Cognition Therapeutics at 1.95 subject to Rule 16b-3 |
Cognition Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.937) % which means that it has lost $0.937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0831) %, meaning that it created substantial loss on money invested by shareholders. Cognition Therapeutics' management efficiency ratios could be used to measure how well Cognition Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.77 in 2024. Return On Capital Employed is likely to drop to -2.13 in 2024. At this time, Cognition Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 962.3 K in 2024, whereas Total Assets are likely to drop slightly above 35 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jim Murray | Tscan Therapeutics | N/A | |
| Alexander Swan | Autolus Therapeutics | 59 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Michael Louie | Kodiak Sciences | N/A | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Richard MD | Lyra Therapeutics | 61 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Maria MBA | Dermata Therapeutics | 73 | |
| Pablo MD | Kodiak Sciences | N/A | |
| Nathan Ihle | Bolt Biotherapeutics | N/A | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Gene MBA | Gain Therapeutics | N/A | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| Nicole Leber | Lantern Pharma | N/A | |
| Jason Amello | Tscan Therapeutics | 56 | |
| Alex Driggs | Autolus Therapeutics | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Michael Alonso | Bolt Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.94 |
Cognition Therapeutics Leadership Team
Elected by the shareholders, the Cognition Therapeutics' board of directors comprises two types of representatives: Cognition Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cognition. The board's role is to monitor Cognition Therapeutics' management team and ensure that shareholders' interests are well served. Cognition Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cognition Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Weissman, VP CMC | ||
| Bobby Horn, Corporate Controller | ||
| Lisa Ricciardi, President CEO | ||
| Andrew CPA, Interim Officer | ||
| John Doyle, Chief Officer | ||
| Anita Cornet, Head Quality |
Cognition Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cognition Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.94 | ||||
| Current Valuation | (3.66 M) | ||||
| Shares Outstanding | 41.55 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 24.53 % | ||||
| Number Of Shares Shorted | 815.7 K | ||||
| Price To Book | 1.23 X | ||||
| EBITDA | (25.51 M) | ||||
| Net Income | (25.79 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.